Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment

Hypomethylating agents (HMAs) are widely used in patients with higher-risk MDS not eligible for stem cell transplantation. However, the general response rate by HMAs is lesser than 50% in MDS patients, while the relapse rate is high. Emerging evidence indicates that demethylating effects committed b...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Suxia, Xu, Ruohao, Huang, Xin, Li, Minming, Deng, Chengxin, Lai, Peilong, Wang, Yulian, Wu, Ping, Chen, Xiaomei, Weng, Jianyu, Du, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393298/
https://www.ncbi.nlm.nih.gov/pubmed/36003379
http://dx.doi.org/10.3389/fimmu.2022.950134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393298/
https://www.ncbi.nlm.nih.gov/pubmed/36003379
http://dx.doi.org/10.3389/fimmu.2022.950134

Ejemplares similares